Target intelligence / Profile preview

Ubiquitin-conjugating enzyme E2 D1 (UBE2D1)

Target
UBE2D1
Molecular classification
Enzyme, Ubiquitin-conjugating enzyme (E2)
01

Overview

Ubiquitin-conjugating enzyme E2 D1 (UBE2D1) is a member of the UbcH5 family of E2 enzymes that mediates the transfer of ubiquitin from ubiquitin-activating enzymes (E1s) to substrate proteins, in cooperation with various E3 ubiquitin-protein ligases. It is central to the polyubiquitination process, which tags proteins for degradation by the proteasome, and helps regulate cellular processes such as the cell cycle, DNA damage repair, immune signaling, and iron metabolism. UBE2D1’s specificity and enzymatic activity are modulated by interactions with other proteins and post-translational modifications. Dysregulation of its expression or activity is linked to several disease states, especially cancer, where it can promote degradation of tumor suppressors like p53 and influence outcomes. UBE2D1 thus represents an important point of regulation in protein homeostasis and cellular signaling.

Other names
SFTUBC5AUBCH5UBCH5AUbcH5AUBC4/5E2(17)KB1Ubiquitin carrier protein D1UBC4/5 homologStimulator of Fe transportUbiquitin-protein ligase D1Ubiquitin-conjugating enzyme E2-17 kDa 1Ubiquitin-conjugating enzyme E2(17)KB 1E2 ubiquitin-conjugating enzyme D1
02

Mechanism of action

Experimental UbVs (ubiquitin variants) bind the backside of UBE2D1, inhibiting its interaction with E1 and E3, attenuating ubiquitin chain formation on substrates. Polyubiquitination by UBE2D1 targets proteins for degradation via the proteasome, regulating the levels of numerous signaling proteins and cell cycle regulators. UBE2D1 partners with RING-type E3 ligases to catalyze ubiquitin transfer, and its conformation can influence the specificity and length of ubiquitin chains (K11, K48, K63 linkages).

03

Biological functions

Protein ubiquitination (regulates proteasomal degradation of proteins)Cell cycle regulationDNA repair (especially double-strand break repair)Regulation of tumor suppressors (e.g., p53)Cholesterol homeostasisIron metabolism (liver, neuronal, hereditary hemochromatosis)Regulation of immune signaling and antigen-presenting molecule turnoverMitotic progressionTranscriptional control (histone ubiquitination)
04

Disease associations

Cancer (lung adenocarcinoma, hepatocellular carcinoma; regulates p53 stability)Hereditary hemochromatosis (iron metabolism)Immune regulation (antigen presentation, interferon response)Neurodegenerative processes (implicated by synaptic regulation and iron transport)Generalized involvement in stress response and genomic stability
05

Safety considerations

Context-dependent safety concerns related to interference with normal protein homeostasis, cell cycle regulation, and immune functionInhibition may affect essential processes, including DNA repair and membrane receptor recycling, leading to possible cytotoxicity or unanticipated cellular dysfunctionNo direct clinical safety profile for UBE2D1-targeting drugs documented
06

Interacting drugs

Engineered ubiquitin variants (UbVs)
07

Biomarkers

UBE2D1 RNA/protein expression (increased mRNA in lung adenocarcinoma predicts poor prognosis)Aberrant activity or levels in liver/hemochromatosisPotential as a biomarker for p53 degradation activity

Beyond the preview

Go deeper on Ubiquitin-conjugating enzyme E2 D1 (UBE2D1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ubiquitin-conjugating enzyme E2 D1 (UBE2D1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call